June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Retrospective Study of Anti-Vascular Endothelial Growth Factor Therapy in the Treatment of Branch Retinal Vein Occlusion and Predictive Factors for Visual Outcome
Author Affiliations & Notes
  • Peng Lei
    Ophthalmology, University of Texas Southwestern, Dallas, TX
  • Footnotes
    Commercial Relationships Peng Lei, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1129. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Peng Lei; Retrospective Study of Anti-Vascular Endothelial Growth Factor Therapy in the Treatment of Branch Retinal Vein Occlusion and Predictive Factors for Visual Outcome. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1129.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To compare the efficacy of bevacizumab and ranibizumab intravitreal injection in the treatment of branch retinal vein occlusion (BRVO). To assess the prognostic value on visual outcome of the integrity of the inner segment-outer segment (IS-OS) junction line on optic coherence tomography (OCT) and the integrity of the foveal capillary ring on fluorescein angiography (FA).

Methods: A retrospective study with 8 patients diagnosed with BRVO; 5 patients received bevacizumab intravitreal injections; 3 patients received ranibizumab intravitreal injections. Average follow up times were 8 months and 6.5 months, respectively. Primary outcomes included difference between initial best corrected visual acuity (BCVA) and best BCVA during follow up, integrity of IS-OS junction, and integrity of foveal capillary ring.

Results: In the bevacizumab group, average improvement in BCVA was 0.375 +/- 0.205 logMAR. Best BCVA was achieved on average after 2.2 +/- 1.6 months and 1.4 +/- 1.1 intravitreal injections. In the ranibizumab group, average improvement in BCVA was 0.141 +/- 0.151 logMAR. Best BCVA was achieved on average after 2.4 +/- 2.2 months and 2.0 +/- 1.7 intravitreal injections. In the bevacizumab group, average improvement in CMT was 404 +/- 41 um with best CMT occurring on average after 1.1 +/- 0.1 months and 1.0 +/- 0.0 injections. In the ranibizumab group, average improvement in CMT was 286 +/- 47 um with best CMT occurring on average after 2.7 +/- 1.1 months and 2.5 +/- 0.7 injections.

Conclusions: Bevacizumab may be superior to ranibizumab for treating BRVO with greater improvement in BCVA, fewer injections to achieve best BCVA, fewer injections needed during follow up course, greater improvement in CMT, shorter time interval to best CMT, and fewer injections needed to achieve best CMT. The integrity of the IS-OS junction correlated well with visual acuity response to anti-VEGF treatment. The integrity of the foveal capillary ring in relation to visual outcome was equivocal. Statistical significance was limited by the small sample size.

Keywords: 688 retina • 749 vascular occlusion/vascular occlusive disease • 748 vascular endothelial growth factor  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×